Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Promis Dx Attend 2023 AUA Conference in Chicago

Irvine, California, April 7, 2023

Promis Dx, Inc., a molecular diagnostics company focused on the early detection of cancer, has announced plans to attend the upcoming 2023 American Urological Association (AUA) annual conference in Chicago, IL.

The conference will be held on April 28 – May 1, 2023 in Chicago, IL., which will take place over four days, brings together healthcare professionals, researchers, and industry leaders to discuss the latest advances in urological diagnostics, care, and treatment. At the conference, Promis Dx, Inc. will have a booth where they will showcase their new product, EarlyTect Bladder Cancer Detection (BCD). The EarlyTect Bladder Cancer Detection is a diagnostic test designed specifically for the detection of bladder cancer. EarlyTect Bladder Cancer Detection is a non-invasive urine-based test that analyzes a patient’s urine sample for specific biomarkers associated with bladder cancer. The test measures the methylation levels of certain genes that are overexpressed in bladder cancer cells, and it can detect the presence of bladder cancer even in its early stages. The test is designed to be a more accurate and less invasive alternative to traditional diagnostic methods for bladder cancer, such as cystoscopy and cytology. Visitors to Promis Dx, Inc.'s booth will be able to see the new test in action and learn more about its features and benefits. The device is expected to generate significant interest among conference attendees, who are always looking for innovative solutions to improve patient care. Also, our new test regarding bladder cancer detection will be presented at the Late-Breaking Abstract Podium Presentation session of the AUA Annual Meeting, which brings together urology professionals from around the world to share the latest research and advances in the field.

Overall, Promis Dx, Inc.’s attendance at the AUA conference is expected to be a success, providing them with the opportunity to promote their new product and connect with other leaders in the urological field. The company remains committed to advancing the field of urology through innovative products and services and looks forward to attending future conferences and events.

For more information about AUA and the speakers presenting, visit https://www.auanet.org/AUA2023.